TrialPloS one2022
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Tadashi Uwagawa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
TrialPloS one2022
Tadashi Uwagawa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.